|Videos|February 24, 2012

New Hepatitis C Treatment

The standard treatment for hepatitis C, interferon and ribavirin, cures just 45% of those who receive it. There are now several dozen new drugs for the disease under development, and 2 were approved by the FDA in 2011: telaprevir and boceprevir. The new drugs, which directly attack the virus that causes hepatitis C with minimal impact on the human host, have raised hopes of shorter treatment times and higher cure rates. Researchers are also looking at ways of tailoring treatment to individual patients based on genetic testing.

To learn more, check out this video:

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

New Hepatitis C Treatment

Related Content

The Biosimilar Conversation Nobody Is Having at the Pharmacy Counter: Why Adoption Is Still Struggling and What We Can Do About It

Updated 2025-2026 COVID-19 Vaccine Nearly Halved ED Visits, Hospitalizations in CDC-Funded Study

Centanafadine Demonstrates Statistically Significant, Clinically Relevant Improvements in ADHD Symptoms

What Criteria Identify a Patient With CRSwNP as a Biologic Candidate?

CSU Management: From Antihistamine Escalation to Targeted Biologic Therapy

Latest CME

The Changing Paradigm in Pain Management and Supporting Access to Novel Therapies

Breast Cancer Day of Education 2026

Neuropsychiatry Day of Education 2026

Translating KDIGO Updates and Clinical Evidence Into Managed Care Decision-Making in IgA Nephropathy

Expert Insights on the Horizon of HER2-Directed Therapy

From Flares to Freedom: Navigating the Journey of Patients With Chronic Spontaneous Urticaria With Next-Generation Therapies

Payment for Pharmacist Services: 2025 Update

Innovations in Hidradenitis Suppurativa Treatment: Navigating the Evolving Landscape

From Molecules to Medicine: Pharmacologic Principles of Innovative Non-Hodgkin Lymphoma Therapies

The Pharmacist's Role in Palliative and End of Life Symptom Management (Pharmacy Technician Credit)

Clinical Panel Debate: CAR T-Cell Therapy vs Bispecific Antibodies

The Pharmacist's Role in Palliative and End of Life Symptom Management

Understanding mRNA Vaccines: Dispelling Myths and Empowering Pharmacists to Counsel Patients (Pharmacy Technician Credit)

Understanding mRNA Vaccines: Dispelling Myths and Empowering Pharmacists to Counsel Patients

Precision Matters: Foundations of Biomarker-Driven Care in Non-Small Cell Lung Cancer

Navigating the Legal Landscape of Telehealth: Updates and Implications for Pharmacists and Technicians (Pharmacy Technician Credit)

Navigating the Legal Landscape of Telehealth: Updates and Implications for Pharmacists and Technicians

From Testing to Treatment: Empowering Pharmacists to Overcome Barriers and Optimize Biomarker-Driven Care

Protecting Against Meningococcal Disease: Updates on Vaccines, Guidelines, and Pharmacist Best Practices

Addressing Vaccine Hesitancy in Infectious Disease Prevention

Targeting the Root of Autoimmunity in Generalized Myasthenia Gravis: Pharmacist Strategies for Integrating FcRn Therapies Into Specialty Practice

IL-23 Inhibitors in Psoriasis: Optimizing Access and Patient Outcomes Across Integrated Systems

Utilizing VMAT-2 Inhibitors for the Management of Tardive Dyskinesia: The Role of Long-Term Care Pharmacists

The Expanding Therapeutic Landscape in IgA Nephropathy: Translating New Clinical Evidence and Updated Guidelines Into Managed Care Strategies

From Guidelines to Action: Implementing Pneumococcal Vaccine ACIP Recommendations in Long-Term Care Settings

Influenza Immunization in Older Adults: Enhanced Vaccines and Best Practices for Long-Term Care Pharmacists

New Horizons in ATTR-CM: Therapeutic Advances and Strategic Insights

Multidisciplinary Insights and Strategies for Patients Treated With PI3K and AKT Inhibitors to Prevent Hyperglycemia

Cardiorenal Protection With SGLT2 Inhibitors: Perspectives for Managed Care

Bridging Innovation and Access in HR-Positive/HER2-Negative Metastatic Breast Cancer: Implications for Managed Care

Navigating Advanced Prostate Cancer Treatment: Optimizing Novel Therapeutic Strategies for Managed Care Pharmacists

Advancing Treatment Strategies in Extensive-Stage Small Cell Lung Cancer: Enhancing Pharmacist Competence in Therapy Selection, Administration, and Adverse Event Management

Beyond the Nasal Passage: Managing Chronic Rhinosinusitis With Nasal Polyps With Biologics and Pharmacist-Led Approaches

New Therapeutic Targets in the Treatment of Generalized Myasthenia Gravis: Understanding Disease Pathways and Pharmacist-Led Strategies for Optimized Care

Pharmacists at the Forefront: Enhancing Targeted Therapy Implementation and Patient Outcomes in Advanced Gastric Cancer

Managing Overactive Bladder in Older Adults: Challenges and Strategies for Long-Term Care

Best Practice Approaches for Understanding Chronic Obstructive Pulmonary Disease and Precision Medicine Treatment

From Payload to Patient: Managing Toxicities of Antibody-Drug Conjugates Directed at HER2 and TROP2

Collaborative Practice Agreement Implementation and Adherence: A Practical Roadmap for Oncology Pharmacists

The Educated Pharmacist: Overcoming Clinical Inertia—An Interactive Case Workshop for Optimizing Insulin Use

Enhancing Patient Outcomes in Metastatic Colorectal Cancer: Equipping Community, Veterans Affairs, and Oncology Pharmacists to Navigate Care in the Third-Line Setting and Beyond

Outsmart the Algorithm: Combatting Misinformation at the Pharmacy Counter

Lymphoma Day of Education 2026

Transforming Gout Care: Navigating Barriers and Therapeutic Advances in Disease Management

Managing Steroid-Refractory Chronic Graft-versus-Host Disease With Novel Therapies: Opportunities for Pharmacist-Led Interventions

Sugar, We’re Going Down: Navigating Glycemic Control in the Era of PI3K/AKT Inhibition for Breast Cancer

Advancing the Idiopathic Pulmonary Fibrosis Treatment Landscape: What’s Next in Care

Exploring Immunotherapy Strategies in Endometrial Cancer

Two Targets, One Mission: Optimizing Bispecific Antibody Use in Non-Hodgkin Lymphoma

Advancing Chronic Kidney Disease Detection and Cardiovascular Risk Reduction in Complex Patients

Navigating the Complexities of Personalized Prostate Cancer Care: Insights for Oncology Managed Care

Hat Trick for Hypertension: Strategies to Improve Outcomes With Single-Pill Combinations

Redefining Complement-Mediated Kidney Disease: The Latest in Diagnosis and Treatment

Advancing Pharmacist Expertise in R/R FL: Navigating Novel Therapies and Optimizing Patient Outcomes

Paroxysmal Nocturnal Hemoglobinuria: Managed Care Strategies to Mitigate Burden and Enhance Outcomes

Optimizing Outcomes in Myasthenia Gravis: Therapeutic Advances and Value-Based Care Models

Navigating Novel Therapies in Steroid-Refractory cGVHD: Practical Strategies for Community-Based Oncology Pharmacists

Reducing Transfusion Burden in Myeloid Disorders: Novel Therapeutic Strategies and Pharmacist Interventions

Managing Iron Replacement Therapies for Patients With Inflammatory Bowel Disease

Iron Deficiency Anemia Treatment Considerations in Women’s Health

Exploring ATTR Phenotypes and Identifying Appropriate Opportunities for Pharmacists to Intervene

Personalizing Treatment in Relapsed/Refractory Multiple Myeloma: The Evolving Role of Antibody-Drug Conjugates and Bispecific Antibodies

Advances in Castration-Sensitive Prostate Cancer: A Pharmacist's Approach to Optimize Novel Antiandrogen Therapies

Pharmacists at the Forefront: Enhancing Immunotherapy Strategies in Endometrial Cancer

Neuropsychiatry Day of Education 2026

Securing the Supply Chain: The Pharmacists’ Role in DSCSA Compliance

Expanding the Role of Long-Acting Injectables in Optimizing Schizophrenia Management

VMAT2 Inhibitors for Long-Term Success in Tardive Dyskinesia

Shifting Perspectives in Treatment-Resistant Depression: Novel Therapies and Patient-Centered Care

Bridging Knowledge Gaps in HR+/HER2– Early-Stage Breast Cancer

Optimizing HER2-Directed Therapy in Metastatic Breast Cancer: From HER2-Positive to HER2-Ultralow

Shaping the Future of Generalized Myasthenia Gravis Management: A Focus on Novel Treatment Approaches